Cargando…

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

Immune checkpoint blockade is less efficient in patients bearing immunologically ‘cold’ tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies publis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gujar, Shashi, Pol, Jonathan G., Kroemer, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136862/ https://www.ncbi.nlm.nih.gov/pubmed/30221036 http://dx.doi.org/10.1080/2162402X.2018.1442169

Ejemplares similares

Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
por: Gujar, Shashi, et al.
Publicado: (2020)

Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities
por: Kim, Youra, et al.
Publicado: (2021)

Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines
por: Holay, Namit, et al.
Publicado: (2017)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
por: Gujar, Shashi A., et al.
Publicado: (2014)

Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
por: Lovatt, Charlotte, et al.
Publicado: (2023)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy
por: Kumar, Vishnupriyan, et al.
Publicado: (2021)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Zika virus oncolytic activity requires CD8(+) T cells and is boosted by immune checkpoint blockade
por: Nair, Sharmila, et al.
Publicado: (2021)

Trial Watch:: Oncolytic viruses for cancer therapy
por: Pol, Jonathan, et al.
Publicado: (2014)

Shaping the “hot” immunogenic tumor microenvironment by nanoparticles co‐delivering oncolytic peptide and TGF‐β1 siRNA for boosting checkpoint blockade therapy
por: Phung, Cao Dai, et al.
Publicado: (2022)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
por: Cruickshank, Brianne, et al.
Publicado: (2018)

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
por: Kim, Youra, et al.
Publicado: (2015)

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
por: Liu, Yang, et al.
Publicado: (2020)

Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade
por: Inoue, Mitsuko, et al.
Publicado: (2021)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
por: Lee, Ju Yeon, et al.
Publicado: (2016)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
por: Wang, Dongdong, et al.
Publicado: (2023)

Trial watch: Oncolytic viruses for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Perspectives on immunotherapy via oncolytic viruses
por: Reale, Alberto, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
por: Leone, Robert D., et al.
Publicado: (2015)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qk9d8lmc31l8dmik7i0oe2bcik